SCHEMBL6067974

SCHEMBL6067974

CCOC(=O)CCCNC(=O)Nc1nc2ccc(Cl)cc2s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.67
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
DYRK1A Q13627 1/20 0.55
FSCN1 Q16658 1/20 0.55
ABL1 P00519 7/20 0.52
CASP3 P42574 4/20 0.52
SENP7 Q9BQF6 4/20 0.52
LCK P06239 1/20 0.52
SENP8 Q96LD8 3/20 0.49
SENP6 Q9GZR1 3/20 0.49
DCLK1 O15075 1/20 0.48
FES P07332 1/20 0.48
PIM1 P11309 1/20 0.48
CDK2 P24941 1/20 0.48
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48
IRAK1 P51617 1/20 0.48
MAP4K2 Q12851 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6068192 0.88 RAB9A (0.57) PTPN1NPC1RAB9ASMN1; SMN2DYRK1A
SCHEMBL2791913 0.87 PTPN1 (0.69) PTPN1NPC1RAB9ASMN1; SMN2DYRK1A
SCHEMBL2790525 0.85 NPC1 (0.73) NPC1RAB9ASMN1; SMN2DYRK1AABL1
SCHEMBL6067978 0.85 DYRK1A (0.58) PTPN1NPC1RAB9ASMN1; SMN2DYRK1A
SCHEMBL13615361 0.84 ABL1 (0.58) PTPN1NPC1RAB9ASMN1; SMN2ABL1
SCHEMBL6067997 0.82 DYRK1A (0.71) PTPN1NPC1RAB9ASMN1; SMN2DYRK1A
SCHEMBL3711260 0.80 ABL1 (0.54) NPC1RAB9ASMN1; SMN2ABL1
SCHEMBL2793299 0.79 PTPN1 (0.66) PTPN1NPC1RAB9ASMN1; SMN2DYRK1A
SCHEMBL2816736 0.78 RAB9A (0.72) NPC1RAB9ASMN1; SMN2DYRK1AABL1
SCHEMBL4920771 0.76 PTPN1 (0.65) PTPN1NPC1RAB9ASMN1; SMN2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091227-B2 Benzothiazole derivatives ABBOTT GMBH & CO. KG (DE) 2006-08-15 US disclosed
US-20030153568-A1 Benzothiazole derivatives BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY 2003-08-14 US disclosed
EP-1254123-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS Abbott GmbH & Co. KG (DE) 2002-11-06 EP disclosed
WO-2001057008-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153568-A1 Benzothiazole derivatives TK1, FLT1, CDK1 PTPN1 255/4885NPC1 3594/4885RAB9A 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.